2.315

3.33% 0.065

Compass Therapeutics Inc (CMPX)

Overview News Price History Financials Discussions Forecast

Compass Therapeutics Inc stock is traded at $2.315, with a volume of 1.63M. It is up +3.33% in the last 24 hours and up +13.41% over the past month. Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.

Previous Close:

$2.25

Open:

$2.2

24h Volume:

1.63M

Relative Volume:

0.46

Market Cap:

$416.90M

Revenue:

$850.00K

Net Income/Loss:

$-68.17M

P/E Ratio:

-5.6244

EPS:

-0.4116

Net Cash Flow:

$-53.29M

1W Performance:

+4.73%

1M Performance:

+13.41%

6M Performance:

-63.62%

1Y Performance:

-21.72%

1-Day Range:

$2.20

$2.37

1-Week Range:

$2.165

$2.385

52-Week Range:

$1.61

$6.88

Compass Therapeutics Inc Stock (CMPX) Company Profile

Name

Compass Therapeutics Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

617-500-8099

Address

80 GUEST STREET, BOSTON

Employee

Twitter

Next Earnings Date

2026-08-10

Latest SEC Filings

CMPX's Discussions on Twitter

Compare CMPX vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CMPX Compass Therapeutics Inc	2.315	405.20M	850.00K	-68.17M	-53.29M	-0.4116
VRTX Vertex Pharmaceuticals Inc	515.94	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	807.13	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	991.78	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	213.72	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.77	39.31B	5.76B	514.49M	1.10B	4.4813

Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-13-26	Initiated	Craig Hallum	Buy
Jan-05-26	Initiated	William Blair	Outperform
Dec-03-25	Initiated	Canaccord Genuity	Buy
Dec-03-25	Initiated	Cantor Fitzgerald	Overweight
Dec-03-25	Initiated	Citizens JMP	Mkt Outperform
Jul-01-25	Resumed	Raymond James	Outperform
Apr-02-25	Upgrade	Leerink Partners	Market Perform → Outperform
Feb-24-25	Initiated	Guggenheim	Buy
Feb-19-25	Initiated	Piper Sandler	Overweight
Dec-23-24	Initiated	D. Boral Capital	Buy
Nov-15-24	Downgrade	Leerink Partners	Outperform → Market Perform
Sep-16-24	Upgrade	Ladenburg Thalmann	Neutral → Buy
Jan-31-23	Initiated	Jefferies	Buy
Jan-27-23	Initiated	Stifel	Buy
May-23-22	Resumed	H.C. Wainwright	Buy
Mar-15-22	Initiated	Ladenburg Thalmann	Buy
Jan-19-22	Initiated	B. Riley Securities	Buy
Dec-22-21	Initiated	Raymond James	Outperform
Dec-20-21	Initiated	SVB Leerink	Outperform
Dec-15-21	Initiated	Wedbush	Outperform

View All

Compass Therapeutics Inc Stock (CMPX) Latest News

Aug 15, 2026

CMPX Stock Has Retail Buzzing Ahead Of High-Stakes Cancer Drug Trial Update - Stocktwits

Aug 15, 2026

Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Aug 15, 2026